Reports from the Field
Once-daily migraine treatment approved
The Food and Drug Administration recently approved Depakote ER (divalproex sodium extended-release tablets), a once-daily formulation for the prevention of migraine headaches in adults by Abbott Laboratories in Abbott Park, IL.
In a 16-week, multi-center, double-blind, placebo-controlled study of 107 migraine sufferers, patients receiving Depakote had a mean four-week migraine headache rate of 3.5 compared to a mean rate of 5.7 for the placebo group. In a similarly designed second trial of 176 patients, Depakote-treated patients had a mean four-week migraine rate of 3.2 compared to a mean rate of 4.5 for the placebo group.
For more information on Depakote, visit the Abbott Web site at www.abbott.com.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content